Cartalax

Cartalax is a synthetic short peptide bioregulator derived from cartilage tissue. It supports regeneration of the extracellular cartilage matrix, stimulates fibroblast and chondrocyte activity, and may alleviate symptoms of osteoarthritis and other degenerative joint diseases. Commonly used in short injectable cycles with minimal systemic side effects.

• Stimulates fibroblast activity, increasing collagen and proteoglycan synthesis
• Promotes chondrocyte proliferation and enhances cartilage matrix regeneration
• Modulates inflammation by regulating cytokine and matrix metalloproteinase expression

• unit: mg

  low dose: 2

  frequency: Daily

  high dose: 6

  standard dose: 4

  administration route: Subcutaneous (SQ)

• Inject 200 mcg daily for 10–20 days. Repeat every 3–6 months for chronic joint health maintenance. Split into 2–3 smaller daily doses if needed.

common: ["Transient fatigue, mild flu-like sensation (user-reported)","Mild digestive upset, rare (user-reported)"]

sequence: Short peptide bioregulator of cartilage tissue

half life: Approximately 24 hours

degradation: Rapid enzymatic degradation unless administered subcutaneously

molecular formula: Not fully disclosed (synthetic peptide complex)

tissue specificity: High specificity for cartilage, connective tissue, and synovial environments

• Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro.preclinicalPMID 27259496 ↗
• Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.preclinicalPMID 32399807 ↗